Device Advice - Issue 12
Hospital medical devices newsletter
Your update on PHARMAC’s Hospital Medical Devices programme
Issue 12 – 19 August 2015
In this issue
In April, PHARMAC sought feedback on our proposed approach to market share procurement for hospital medical devices. We have now released the summary of feedback from the consultation, and have outlined our next steps.
The discussion document outlined the next stage of our hospital medical devices activity, which would see us offering suppliers an assured portion of the market in return for competitive pricing and quality products. We proposed that a group of subcategories within wound care would be the first to be considered for a market share procurement approach.
PHARMAC received 23 submissions from a range of stakeholders including clinical submitters, devices suppliers, Medical Technology Association of New Zealand (MTANZ), Product Evaluation Health NZ (PEHNZ), and DHBs.
We are using the feedback we received to help us develop a well thought out market share procurement process that is mindful of the potential implications for patients, clinicians, DHBs and suppliers.
The submissions reflected support for our proposed approach, with some reservations and suggestions for improvement. You can read PHARMAC’s response to these concerns, as well as a range of risks and benefits submitters identified, here:
Our next step is to develop a market share procurement process for a limited number of wound care products. This is likely to take the form of a Request for Proposals (RFP) that we expect to issue in September 2015 on the Government Electronic Tender Services (GETS) and on our website (www.pharmac.govt.nz(external link)).
We are keen to continue working alongside and to seek ongoing input from our colleagues in the health sector, building on the relationships and knowledge gained through our work so far.
The summary of submissions is available below.
PHARMAC is pleased to announce the approval of an agreement with N Stenning for the supply of valvuloplasty balloon catheters. The range is available for DHBs to purchase at PHARMAC negotiated prices from 1 August 2015.
This contract represents the fifth agreement in the interventional cardiology category and will deliver savings for the DHBs that currently use these products.
We are continuing further negotiations with existing DHB suppliers within the interventional cardiology category to secure more national agreements that will deliver further savings.
This agreement was the subject of a consultation letter dated 12 June 2015. The list of products is available in both a PDF document and a series of Excel spreadsheets in Section H, Part III of the Pharmaceutical Schedule.
We are planning on another series of DHB based forums to take place in October and early November. We will forward through details on the locations and timings later this month. In the meantime, if there are particular areas of interest you would like to see the forums cover, please let us know. You can email us at email@example.com.
Last updated: 19 November 2018